Evidence map›Paper›PMID 42749420›Full record

ArticleJournal, genetic engineering & biotechnology2026

Alteration in adenosine monophosphate deaminase activity and ferric reducing capacity in diabetic renal failure patients.

Lubna Sameer Hammad, Jwan Abdulmohsin Zainulabdeen

Abstract read
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lubna Sameer HammadDepartment of Chemistry, College of Science, University of Baghdad, Baghdad. Iraq. Electronic address: Lobna.Samir1805a@sc.uobaghdad.edu.iq.
Jwan Abdulmohsin ZainulabdeenDepartment of Chemistry, College of Science, University of Baghdad, Baghdad. Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal failure is the final stage of chronic kidney disease (a common complication of diabetic mellitus) usually occurs due to delayed treatment or poor disease control with Glomerular filtration Rate falling below 15 mL/min leading to severe deterioration of renal function. Meanwhile Adenosine Monophosphate Deaminase (AMPD) participate in purine metabolism; affecting energy balance.The aim of this study was to investigate the diagnostic significance of AMPD activity with some parameters including ferric reducing capacity (FRC) as an indicator of oxidative stress.The participants of the work divided into: healthy Subject (H), renal failure patients (RF) and renal failure with diabetes mellitus (RF + DM). The results showed a significant increase in AMPD activity in diabetic RF group than RF group without (25.57 ± 3.06 and 16.30 ± 3.44) as well as when compared with healthy subjects (5.89 ± 1.59), levels of FRC were increased also especially in the RF + DM indicating a compensatory increase in antioxidant capacity in response to oxidative stress that caused from RF and DM. Cluster analysis reveals systematic signature in RF where most parameters are closely correlated identifying sensitive indicators of renal health while FRC demonstrate an independent outlier from traditional filtration metrics. ROC curve showed that both markers had excellent diagnostic accuracy with (AUC = 0.9) indicating that they are strong and early biomarkers for RF particularly in diabetic patients. The findings also suggest that inhibition of AMPD activity may help improve metabolism, reduce inflammation, and oxidative stress leading to providing vital protection against RF.

Indexed as

Adenosine monophosphate deaminaseDiabetes mellitusFerric reducing capacityRenal failure

Identifiers

PMID42749420
PMCPMC13334804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.